ArticleResearch in pharmaceutical sciences2026
Cardioprotective effects of gallic acid in a rat ischemia-reperfusion model: role of apoptosis, inflammation, and antioxidant defense.
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutrophil-mediated myocardial ischemia-reperfusion injury: mechanisms and potential therapeutic targets.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Heart disease is a major global health problem. Gallic acid (GA) possesses cardioprotective properties. This study aimed to evaluate the therapeutic effects of GA pretreatment in ischemia-reperfusion (I/R) and elucidate its underlying mechanisms. Experimental approach: Forty adult male Wistar rats were subjected to this experiment. GA was given to the rats through gavage at doses of 15 and 30 mg/kg/day, 10 days before the induction of ischemia. To induce I/R, the left anterior descending coronary artery was occluded for 30 min, and reperfusion continued for 24 h. Malondialdehyde (MDA) levels, antioxidant enzyme activity, and inflammatory cytokines were assessed using kits. Myocardial injury markers were analyzed by ELISA, and infarct size was assessed through 2,3,5-triphenyltetrazolium chloride staining. Real-time polymerase chain reaction was utilized to quantify the relative gene expression of Findings/Results: The findings indicated that pretreatment with GA led to significant improvement in inflammatory cytokines, antioxidant enzyme activity, and a decrease in MDA levels. GA also decreased infarct size and myocardial injury markers significantly. Moreover, pretreatment with GA revealed a significant increase in the expression of the Conclusion and implications: Inclusively, the results suggested that GA may hold significant potential as a therapeutic agent for reducing myocardial injury in the context of I/R, with 30 mg/kg/day proving more effective than 15 mg/kg/day, offering a promising path for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.